Davison Sara N, Rathwell Sarah, George Chelsy, Hussain Syed T, Grundy Kate, Dennett Liz
Department of Medicine, University of Alberta, Edmonton, Canada.
Kidney Supportive Care Research Group and Department of Medicine, University of Alberta, Edmonton, Canada.
Can J Kidney Health Dis. 2020 Mar 6;7:2054358120910329. doi: 10.1177/2054358120910329. eCollection 2020.
Pain is common in patients with chronic kidney disease (CKD). Analgesics may be appropriate for some CKD patients.
To determine the prevalence of overall analgesic use and the use of different types of analgesics including acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs), adjuvants, and opioids in patients with CKD.
Systematic review and meta-analysis.
Interventional and observational studies presenting data from 2000 or later. Exclusion criteria included acute kidney injury or studies that limited the study population to a specific cause, symptom, and/or comorbidity.
Adults with stage 3-5 CKD including dialysis patients and those managed conservatively without dialysis.
Data extracted included title, first author, design, country, year of data collection, publication year, mean age, stage of CKD, prevalence of analgesic use, and the types of analgesics prescribed.
Databases searched included MEDLINE, CINAHL, EMBASE, and Cochrane Library. Two reviewers independently screened all titles and abstracts, assessed potentially relevant articles, and extracted data. We estimated pooled prevalence of analgesic use and the statistic was computed to measure heterogeneity. Random-effects models were used to account for variations in study design and sample populations, and a double arcsine transformation of the prevalence variables was used to accommodate potential overweighting of studies with very large or very small prevalence measurements. Sensitivity analyses were performed to determine the magnitude of publication bias and assess possible sources of heterogeneity.
Forty studies were included in the analysis. The prevalence of overall analgesic use in the random-effects model was 50.8%. The prevalence of acetaminophen, NSAIDs, and adjuvant use was 27.5%, 17.2%, and 23.4%, respectively, while the prevalence of opioid use was 23.8%. Due to the possibility of publication bias, the actual prevalence of acetaminophen use in patients with advanced CKD may be substantially lower than this meta-analysis indicates. A trim-and-fill analysis decreased the pooled prevalence estimate of acetaminophen use to 5.4%. The prevalence rate for opioid use was highly influenced by 2 large US studies. When these were removed, the estimated prevalence decreased to 17.3%.
There was a lack of detailed information regarding the analgesic regimen (such as specific analgesics used within each class and inconsistent accounting for patients on multiple drugs and the use of over-the-counter analgesics such as acetaminophen and NSAIDs), patient characteristics, type of pain being treated, and the outcomes of treatment. Data on adjuvant use were very limited. These results, therefore, must be interpreted with caution.
There was tremendous variability in the prescribing patterns of both nonopioid and opioid analgesics within and between countries suggesting widespread uncertainty about the optimal pharmacological approach to treating pain. Further research that incorporates robust reporting of analgesic regimens and links prescribing patterns to clinical outcomes is needed to guide optimal clinical practice.
疼痛在慢性肾脏病(CKD)患者中很常见。镇痛药可能适用于一些CKD患者。
确定CKD患者中总体镇痛药的使用情况以及对不同类型镇痛药(包括对乙酰氨基酚、非甾体抗炎药(NSAIDs)、辅助镇痛药和阿片类药物)的使用情况。
系统评价和荟萃分析。
呈现2000年或之后数据的干预性和观察性研究。排除标准包括急性肾损伤或那些将研究人群限制于特定病因、症状和/或合并症的研究。
3 - 5期CKD成人患者,包括透析患者以及未进行透析保守治疗的患者。
提取的数据包括标题、第一作者、设计、国家、数据收集年份、发表年份、平均年龄、CKD分期、镇痛药使用情况以及所开具的镇痛药类型。
检索的数据库包括MEDLINE、CINAHL、EMBASE和Cochrane图书馆。两名评审员独立筛选所有标题和摘要,评估潜在相关文章并提取数据。我们估计了镇痛药使用的合并患病率,并计算统计量以测量异质性。采用随机效应模型来考虑研究设计和样本人群中的差异,并且对患病率变量进行双反正弦变换以适应患病率测量值非常大或非常小的研究可能存在的过度加权情况。进行敏感性分析以确定发表偏倚的程度并评估异质性的可能来源。
40项研究纳入分析。随机效应模型中总体镇痛药使用的患病率为50.8%。对乙酰氨基酚、NSAIDs和辅助镇痛药的使用患病率分别为27.5%、17.2%和23.4%,而阿片类药物的使用患病率为23.8%。由于存在发表偏倚的可能性,晚期CKD患者中对乙酰氨基酚的实际使用患病率可能远低于该荟萃分析所示。修剪填充分析将对乙酰氨基酚使用的合并患病率估计值降至5.4%。阿片类药物使用的患病率受到两项美国大型研究的高度影响。去除这两项研究后,估计患病率降至17.3%。
缺乏关于镇痛方案的详细信息(例如每类中使用的具体镇痛药以及对使用多种药物的患者和使用对乙酰氨基酚和NSAIDs等非处方镇痛药的情况记录不一致)、患者特征、所治疗疼痛的类型以及治疗结果。关于辅助镇痛药使用的数据非常有限。因此,必须谨慎解读这些结果。
各国之间以及各国国内非阿片类和阿片类镇痛药的处方模式存在巨大差异,这表明在治疗疼痛的最佳药理学方法上存在广泛的不确定性。需要进一步开展研究,全面报告镇痛方案并将处方模式与临床结果联系起来,以指导最佳临床实践。